Cancer Cytokines Therapy Pipeline Analysis - Hawaii News Now - KGMB and KHNL

Cancer Cytokines Therapy Pipeline Analysis

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Bharat Book Bureau

MUMBAI, June 20, 2014 /PRNewswire/ --

Cytokines, a major group in the protein therapeutics umbrella, are known to be soluble extracellular proteins or glycoproteins which are crucial intercellular regulators, having the capacity to mobilize the cells which are engaged in innate as well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. These proteins are being used mostly for cancer patients due to their capability to stop tumor growth. Cytokines are considered to be a large, diverse group of extracellular proteins which are produced by the immune system cells. These cytokines have the capacity to be bound by the cytokine receptors on the targeted cells. This process initiates a signaling cascade within those cells. http://bit.ly/1lv8Rqi.

The growth in the cytokines market is mainly driven by its increased application for cancer treating methods, along with an increased spending on research and development, advances in technology, patent expiries, and rising competition. Cytokines are related to almost all the therapeutic protein drug development processes. The cytokine and growth factor related products include antibodies, proteins and nucleic acid probes which are being extensively used in a wide variety of applications from the basic research laboratory through the drug discovery process, to in vivo therapeutic use. The companies producing these proteins are focusing their strategy on offering high quality products at more than competitive prices.

Request Sample Pages: http://bit.ly/1vOaFwN https://www.bharatbook.com/RequestSample.asp?pid=502198

It is expected that in the next 4-5 years, the Pharma companies would focus more on the development of successful cancer therapies based on cytokines. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new cytokines products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. This segment has proved to be the most important investment to control the sprawling rise in cancer incidence rates. Also, from a commercial viewpoint, these cytokine products are likely to churn significant revenues and for the patient population, and eventually are expected to improve the survival rates and improve quality of life.

"Cancer Cytokines Therapy Pipeline Analysis" Report Highlights:

• Cancer Cytokines Therapy Market Overview

• Marketed Drug Profiles & Patent Analysis

• Clinical Trial Insight by Phase & Country

• Drug in Clinical Development Phase: 64

• Majority Therapies in Preclinical Phase: 25

• Marketed Cytokines Therapies: 15

• Suspended & Discontinued Drug Profiles: 67

• Competitive Landscape

Table of Content: 

  • Cancer Cytokines Therapy Market Overview 
  • Cancer Cytokines Therapy Clinical Trial Insight by Phase, Country & Target Indications 
  • Marketed Cancer Cytokines Clinical Profiles & Patent Analysis  
  • Suspended & Discontinued Cancer Cytokines Therapy in Clinical Trial  
  • Competitive Landscape    

To view the Abstract and TOC:  

https://www.bharatbook.com/healthcare-market-research-reports-502198/cancer-cytokines-therapy-pipeline-analysis.html

Related Reports:http://bit.ly/1uCcTww  http://bit.ly/1uCcTww

Contact Details: 

Poonam

Bharat Book Bureau

USA/Canada - 1-866-279-8368 (Toll free)

India: +91-22-27810772, 27810773

Blog: http://blog.bharatbook.com

E: poonam@bharatbook.com

W: www.bharatbook.com


©2012 PR Newswire. All Rights Reserved.